首页> 外文OA文献 >Application of micelle-mediated extraction in preparation of body fluids for HPLC-DAD screening of acidic and neutral drugs
【2h】

Application of micelle-mediated extraction in preparation of body fluids for HPLC-DAD screening of acidic and neutral drugs

机译:胶束介导的萃取在体液制备中用于酸性和中性药物HPLC-DAD筛选的应用

摘要

Experimental conditions of cloud-point extraction (CPE) for the selected five acidic and neutral medicaments (salicylic acid, opipramol, carbamazepine, lorazepam, and alprazolam) in human plasma were studied and optimized. Separation and detection of the tested drugs were performed by the high-performance liquid chromatography with diode array detection (HPLC-DAD) method in an appropriate gradient mode using a column Nucleosil C8. Under the optimized conditions, main validation parameters were determined for all the compounds. The extraction yields (%) ranged from 54.12 to 82.17 with intra- and interday repeatability (RSD, %) 5.70–9.92 and 5.79–10.19, respectively. The detection limit was 0.5 μg mL−1 for all the tested drugs with exception of salicylic acid (LOD = 2.5 μg mL−1). The linearity of the proposed method was examined for the four drugs: opipramol, carbamazepine, lorazepam, and alprazolam in the concentration range of 0.5–2.0 μg mL−1 (correlation coefficient r2 = 0.995–0.999) and for salicylic acid in the concentration range of 2.5–10.0 μg mL−1 (correlation coefficient r2 = 0.993). The analytical parameters for the medicaments tested in whole blood were unsatisfactory, especially in terms of extraction recovery and repeatability, and application of the developed procedure for this biological matrix requires further study.
机译:研究和优化了选定血浆中五种酸性和中性药物(水杨酸,奥匹普拉,卡马西平,劳拉西m和阿普唑仑)的浊点萃取(CPE)实验条件。使用Nucleosil C8色谱柱,通过带有二极管阵列检测(HPLC-DAD)方法的高效液相色谱法,在适当的梯度模式下,进行测试药物的分离和检测。在优化的条件下,确定了所有化合物的主要验证参数。提取率(%)在54.12至82.17之间,日内和日间重复性(RSD,%)分别为5.70-9.92和5.79-10.19。除水杨酸外,所有被测药物的检出限均为0.5μgmL-1(LOD = 2.5μgmL-1)。检验了所提出方法的线性度,适用于浓度范围为0.5–2.0μgmL-1(相关系数r2 = 0.995–0.999)的水杨酸和浓度范围为0.5–2.0μgmL-1的奥匹拉莫,卡马西平,劳拉西m和阿普唑仑2.5-10.0μgmL-1(相关系数r2 = 0.993)。在全血中测试的药物的分析参数不能令人满意,特别是在提取回收率和可重复性方面,开发的用于这种生物基质的程序的应用需要进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号